3-Aminobenzamide (PARP-IN-1): A Potent and Selective Poly (ADP-ribose) Polymerase Inhibitor

Executive Summary: 3-Aminobenzamide (PARP-IN-1) is a well-characterized, small-molecule inhibitor of poly (ADP-ribose) polymerase (PARP) with an IC₅₀ of approximately 50 nM in CHO cells, yielding >95% PARP inhibition at concentrations above 1 μM without notable cytotoxicity (APExBIO). This compound enhances nitric oxide-mediated vasorelaxation after oxidative stress, reduces podocyte depletion in diabetic nephropathy models, and is essential for dissecting PARP-mediated pathways in viral immunity (Grunewald et al., 2019). Its favorable solubility in water, ethanol, and DMSO—combined with high stability at -20°C—enables reproducible integration into a variety of experimental workflows (APExBIO). 3-Aminobenzamide is distributed by APExBIO for research use only, not for diagnostic or clinical application.

Biological Rationale

Poly (ADP-ribose) polymerases (PARPs) are a family of enzymes that catalyze the transfer of ADP-ribose units from NAD⁺ to target proteins, regulating DNA repair, cellular stress response, and innate immunity (Grunewald et al., 2019). Humans encode 17 PARPs, with PARP1 and PARP2 being the primary mediators of poly-ADP-ribosylation. ADP-ribosylation is both reversible and tightly regulated by hydrolases and macrodomains. Dysregulated PARP activation contributes to cell dysfunction and death in settings of oxidative stress, ischemia-reperfusion injury, and chronic diseases like diabetes. Inhibitors such as 3-Aminobenzamide (PARP-IN-1) provide mechanistic insight by blocking NAD⁺-dependent PARP activity, thus modulating DNA repair, cell survival, and inflammatory signaling. These effects underpin its use in research on diabetic nephropathy, cardiovascular dysfunction, and the host-pathogen interface (APExBIO).

Mechanism of Action of 3-Aminobenzamide (PARP-IN-1)

3-Aminobenzamide is a competitive inhibitor of the PARP catalytic site, mimicking NAD⁺ and binding to the ADP-ribosyltransferase domain. By occupying the NAD⁺ binding pocket, it prevents transfer of ADP-ribose to substrate proteins, thereby inhibiting both mono- and poly-ADP-ribosylation reactions. This inhibition is effective at low nanomolar concentrations (IC₅₀ ~50 nM in CHO cells), enabling rapid and reversible suppression of PARP activity during acute experimental windows (APExBIO). 3-Aminobenzamide's selectivity minimizes off-target effects on other NAD⁺-dependent enzymes. In cell models, it reduces oxidant-induced myocyte dysfunction and preserves nitric oxide-dependent vasorelaxation by preventing hyperactivation of PARP and subsequent NAD⁺ depletion. In mouse models of diabetes, it mitigates albuminuria, glomerular mesangial expansion, and podocyte loss—key features of diabetic nephropathy (PrecisionFDA—this article extends the mechanistic detail of PARP inhibition beyond its summary of experimental outcomes).

Evidence & Benchmarks

• 3-Aminobenzamide (PARP-IN-1) inhibits PARP activity in CHO cells with an IC₅₀ of approximately 50 nM, achieving >95% inhibition at >1 μM without significant cytotoxicity (APExBIO).
• PAN-PARP inhibition enhances coronavirus replication in cells lacking functional viral macrodomains, demonstrating the critical regulatory role of PARPs in antiviral immunity (Grunewald et al., 2019, Fig 3–5).
• 3-Aminobenzamide improves acetylcholine-induced, endothelium-dependent, nitric oxide-mediated vasorelaxation in vascular tissue subjected to hydrogen peroxide-induced oxidative stress (APExBIO).
• In diabetic db/db mice, 3-Aminobenzamide reduces albumin excretion, mesangial matrix expansion, and podocyte depletion, supporting use in diabetic nephropathy research (APExBIO).
• Solubility benchmarks: ≥23.45 mg/mL in water, ≥48.1 mg/mL in ethanol, and ≥7.35 mg/mL in DMSO, all with ultrasonic assistance; stability is optimal at -20°C (APExBIO).

Applications, Limits & Misconceptions

3-Aminobenzamide (PARP-IN-1) is used in a variety of research contexts:

• Oxidative Stress Models: Protects myocytes and endothelial cells from oxidant-induced dysfunction by modulating NAD⁺ consumption and cell death pathways.
• Diabetic Nephropathy Research: Ameliorates features of diabetic kidney injury in vivo, including albuminuria and podocyte loss.
• Viral Infection Studies: Serves as a tool to probe PARP-dependent regulation of viral replication and interferon response (see Grunewald et al., 2019).
• DNA Damage/Repair Assays: Facilitates dissection of PARP1/PARP2 roles in the cellular response to DNA strand breaks.

This article updates and expands on the workflow and troubleshooting focus in Applied Use-Cases of 3-Aminobenzamide, by providing granular evidence and boundary conditions for reliable use in mechanistic and preclinical models.

Common Pitfalls or Misconceptions

• 3-Aminobenzamide does not inhibit non-PARP ADP-ribosyltransferases (such as ARTCs or sirtuins); its specificity is for PARP family enzymes only (Grunewald et al., 2019).
• It is not suitable for clinical or diagnostic use; research use only per APExBIO product guidelines (APExBIO).
• Long-term storage of reconstituted solutions is discouraged due to potential hydrolysis; always prepare fresh aliquots for reproducibility (APExBIO).
• High concentrations (>10 μM) may have off-target effects in some cellular systems; titration is recommended for each assay.
• Not all PARP-dependent cellular phenotypes are reversible using 3-Aminobenzamide; some effects may be downstream or independent of PARP activity.

Workflow Integration & Parameters

3-Aminobenzamide (PARP-IN-1) is provided as a solid, with a molecular weight of 136.15 g/mol and chemical formula C₇H₈N₂O (APExBIO). For experimental use, it is dissolved at ≥23.45 mg/mL in water, ≥48.1 mg/mL in ethanol, or ≥7.35 mg/mL in DMSO using ultrasonic assistance. Solutions should be freshly prepared and stored at -20°C for short periods. It ships under Blue Ice to ensure stability. For PARP activity assays, recommended working concentrations are 0.05–10 μM, with validation in cell-based or biochemical systems.

For further workflow strategies, advanced troubleshooting, and comparative analysis of PARP inhibitors, see 3-Aminobenzamide (PARP-IN-1): Unlocking Potent PARP Inhibition—this article builds on those insights by presenting more detailed evidentiary benchmarks and clarifying boundaries of utility.

Conclusion & Outlook

3-Aminobenzamide (PARP-IN-1) from APExBIO is a reference-standard, potent PARP inhibitor with validated use across DNA repair, oxidative stress, and disease modeling research. Its specificity, solubility, and low toxicity profile enable precise modulation of PARP activity in both cellular and animal models. Recent studies—including pivotal work on PARP in viral immune regulation—highlight the translational and mechanistic value of this compound (Grunewald et al., 2019). For detailed protocols and product specifications, visit the 3-Aminobenzamide (PARP-IN-1) product page.